Hongkang Zhang
VP, Head of Pain Therapeutics Research Quiver Bioscience
In his role as Senior Director, Pain Therapeutics Lead at Quiver Bioscience, Hongkang Zhang manages a team of scientists and researchers to develop non-opioid therapeutics, including small molecules and antisense oligonucleotides, for chronic pain treatment. He has over 15 years of experience in leading research projects in the academic and biotech industry sectors, studying channelopathy related disorders including pain, epilepsy and cardiac arrhythmias. Hongkang received a B.S. in Biology from Peking University and a Ph.D. in Neuroscience from Johns Hopkins University. He finished his postdoctoral training in the Chemistry Department of Harvard University.
Seminars
Thursday 20th August 2026
Expanding Oligonucleotide Therapeutics into Pain: Platform-Enabled Targeting of NaV1
9:00 am
- Leveraging antisense oligonucleotides (ASOs) to modulate NaV1.7 expression as a novel non-opioid therapeutic strategy for chronic pain
- Positioning pain as an emerging and underexplored indication for oligonucleotide therapeutics beyond rare genetic and neurodegenerative diseases
- Applying AI and machine learning–enabled approaches to optimize ASO sequence and chemistry selection, improving target engagement and therapeutic index in preclinical development
